Background: The simian malaria parasite Plasmodium knowlesi is now a well-recognized pathogen of humans in South-East Asia. Clinical infections appear adequately treated with existing drug regimens, but the evidence base for this practice remains weak. The availability of P. knowlesi cultures adapted to continuous propagation in human erythrocytes enables specific studies of in vitro susceptibility of the species to antimalarial agents, and could provide a surrogate system for testing investigational compounds against Plasmodium vivax and other non-Plasmodium falciparum infections that cannot currently be propagated in vitro.
Introduction
One of six species of Plasmodium that infect humans, the zoonotic parasite Plasmodium knowlesi is increasingly recognized as an important contributor to malaria infection in South-East Asia, including Malaysia, Myanmar and Indonesia. [1] [2] [3] Infections are characterized by the rapid (24 h) schizogonic cycle, can be severe and are occasionally lethal. A thorough understanding of P. knowlesi susceptibility to both existing and pipeline antimalarial therapies is critical.
Thus far, in vitro screening of newly developed antimalarial drugs has been limited to Plasmodium falciparum-the only tractable human malaria species in vitro until the recent adaptation of P. knowlesi to continuous culture in human erythrocytes. [4] [5] [6] Originally isolated from a Malaysian macaque in the 1960s, the culture-adapted isolate has no history of exposure to antimalarial drugs and provides an unselected genetic background on which to screen new antimalarials by assessment of parasite susceptibility in vitro. As early as 2004, incorporation of [ 3 H]hypoxanthine was used to monitor growth of P. knowlesi cultured in rhesus erythrocytes following exposure to selective agents used for transfection, 7 and in human erythrocyte-adapted P. knowlesi cultures. 8 Ex vivo drug susceptibility has been investigated using the microscopybased WHO microtest and the colorimetric lactate dehydrogenase (LDH) assay. 9 All studies thus far have failed to address key differences in P. knowlesi biology that may reduce applicability of standard assays developed for P. falciparum. These include albumin content of growth media, differences in life cycle length and contrasting multiplication rates. Thus meaningful, adequately controlled comparisons of in vitro drug susceptibility in the two parasite species have yet to be reported.
We assess the susceptibility of P. knowlesi cultured in human red cells against a panel of current and experimental antimalarial agents, in comparison with drug-susceptible P. falciparum (3D7). We evaluate assays using the DNA intercalating fluorescent dye SYBR Green I, and the LDH-based colorimetric assay, to measure parasite growth inhibition in vitro, and in so doing elucidate detailed susceptibility profiles for several compound classes.
Materials and methods

Drugs
Antimalarial compounds were provided by the Medicines for Malaria Venture, Geneva, Switzerland. Drug stocks were prepared in DMSO except chloroquine and blasticidin, which were prepared in sterile distilled water.
Parasite culture
P. knowlesi (A1-H.1 clone) was cultured as described previously with minor modifications. 10 Briefly, parasites were maintained at 2% haematocrit in RPMI 1640 supplemented with 25 mM HEPES, 25 mM Na 2 HCO 3 , 10mM D-glucose, 2 mM L-glutamine, 25 mg/L gentamicin sulphate, 50 mg/L hypoxanthine, 5 g/L Albumax II and 10% (v/v) equine serum (Thermo Fisher Scientific, 26050-070). For routine culturing P. falciparum (3D7 clone) was maintained in identical growth medium, supplemented with 2% heatinactivated human serum (Sigma-Aldrich, H4522) in place of the equine serum. For drug assays, unless stated, both parasite species were grown in the P. knowlesi growth medium/serum mix. Both P. knowlesi and P. falciparum parasites were grown in human A ! blood (National Health Blood and Transplant, UK). Some experiments were performed in blood from Macaca fascicularis, provided by NIBSC (UK) in K 2 EDTA vacutainers (Becton Dickinson). Parasites were incubated at 37 C under a culture gas mixture of 93% N 2 , 4% CO 2 and 3% O 2 .
Synchronization
P. knowlesi schizont culture was adjusted to 50% haematocrit in RPMI medium; 2 mL was layered on top of 5 mL of 55% Nycodenz solution in 10 mM HEPES (pH 7.0) and centrifuged at 900 g for 12 min. The pigmented interphase containing mature parasites was removed and washed in RPMI then returned to culture with fresh red cells. 6 P. falciparum parasites were synchronized with 5% (w/v) D-sorbitol as described previously.
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Growth inhibition assays
Drug susceptibility of P. knowlesi and P. falciparum was assayed using 96-well flat-bottomed microplates, with 100 lL of parasite stock added to 100 lL of drug dilution in medium per well. Drug-free control wells were included in each experiment and background fluorescence determined in parasite-seeded wells containing a supralethal concentration of chloroquine (10 lM). The plates were incubated at 37 C in an incubation chamber (Billups-Rothenburg Inc.) under culture gas, and then stored at -20 C overnight.
Microplates were thawed and incubated with 100 lL of SYBR Green lysis buffer [1:5000 SYBR Green I (Thermo Fisher Scientific, S7563), diluted in 20 mM Tris, 5 mM EDTA, 0.008% (w/v) saponin, 0.08% (v/v) Triton X-100, pH 7.5] in the dark for 1 h, before fluorescence was read in a Spectramax M3 microplate reader (Molecular Devices) at 490 nm excitation and 520 nm emission.
The colorimetric LDH assay was performed as described for P. falciparum. 
Time course
To test for the effect of parasite synchrony on drug responses, we initiated a time course of drug susceptibility assays at 6 or 12 h intervals across the P. knowlesi and P. falciparum life cycles of 27 and 48 h, respectively. Latestage parasites were synchronized with a 2 h window using sequential Nycodenz purification as described previously. 6 New ring stages (0-2 h post-invasion) were diluted to 1% parasitaemia and exposed to drugs (as described above) for one or two life cycles (27 or 54 h for P. knowlesi A1-H.1 6 and 48 or 96 h for P. falciparum 3D7). From this parasite stock, subsequent drug assays on P. knowlesi were initiated every 6 h for 24 h and on P. falciparum every 12 h for 36 h.
Statistics
Z 0 factors were calculated to measure the assay quality as described previously, 17 using assay plates containing six negative control wells and six positive control wells. Assays with Z 0 values lying between 0.5 and 1.0 are considered indicative of a robust assay performance. P values were calculated using Student's two-tailed t-test for unpaired or paired samples.
Results and discussion
Effect of starting parasitaemia and haematocrit on non-isotopic growth assays Although previously used for parasite growth assay in P. knowlesi, 7, 8, 18 the requirement for radiolabelled hypoxanthine and specialized equipment prevent the [ 3 H]hypoxanthine incorporation assay from being widely implemented. We therefore focused our attention on optimization of two non-isotopic methods, namely the fluorometric SYBR Green I assay and the colorimetric LDH enzyme assay, to measure and compare in vitro drug susceptibility between P. knowlesi and P. falciparum.
P. knowlesi and P. falciparum parasites were diluted to a series of starting parasitaemia at 1% haematocrit ( Figure 1 ) or 2% haematocrit ( Figure S1 , available as Supplementary data at JAC Online). Whilst the P. knowlesi life cycle in vivo is 24 h, the life cycle in vitro takes longer at 27 h, and incubation times were modified accordingly. Cultures were therefore incubated in the presence or absence of drugs for one, two or three complete life cycles: 27, 54 and 81 h for P. knowlesi; 48 and 96 h for P. falciparum.
For P. knowlesi, the SYBR Green I assay produced high-quality results for a single life cycle exposure (27 h) using a starting parasitaemia of 1% and 1% haematocrit ( Figure 1a ). Lower starting parasitaemia also generated good-quality assays if exposed for two (54 h) or three (81 h) life cycles. LDH assays starting at 1% parasitaemia/1% haematocrit yielded assays of only borderline quality and parasitaemia below 1% gave unsatisfactory resultsthus initiating assays at 2% parasitaemia is preferable for this method (Figure 1b) . The signal window improved with longer exposures at all starting parasitaemia for the SYBR Green assay (Figure 1e ) and the LDH assay ( Figure 1f ) but remained ,3.0 for both assay methods.
For P. falciparum, good-quality assays were obtained at starting parasitaemia of 0.25% and 1% haematocrit for a single life cycle van Schalkwyk et al.
(48 h) and at 0.1% parasitaemia/1% haematocrit for two life cycles (96 h) using the SYBR Green I method ( Figure 1c) . Similarly, the LDH assay performed better with P. falciparum down to 0.25% starting parasitaemia ( Figure 1d ). Again, the signal window improved with higher initial parasitaemia and with longer exposures for both the SYBR Green ( Figure 1g ) and LDH assays ( Figure 1h ). The speciesspecific difference in assay quality for both formats is partly explained by the lower multiplication rate per life cycle for P. knowlesi (3-to 4-fold) compared with P. falciparum (6-to 8-fold). Furthermore, the activity of the LDH enzyme is poorly characterized in P. knowlesi relative to P. falciparum.
Effect of synchrony on drug susceptibility measured across the life cycle
Drug susceptibility testing of P. falciparum is usually initiated using sorbitol-synchronized ring-stage parasites. P. knowlesi is less amenable to sorbitol synchronization, requiring density gradient synchronization instead, and also loses synchrony rapidly in vitro.
To examine the effect of synchrony on susceptibility to antimalarial agents, a time course was initiated with synchronized P. knowlesi or P. falciparum exposed to chloroquine, dihydroartemisinin or pyrimethamine for one and two complete life cycles, and results compared between the SYBR Green I fluorescence method ( Figure  2 ) and the colorimetric method ( Figure S2 ).
In the fluorescence assay after one cycle with P. knowlesi, the initial life cycle stage had little effect on the EC 50 for either the endoperoxide dihydroartemisinin or the antifolate pyrimethamine, but the EC 50 varied dramatically with chloroquine ( Figure 2a) . For P. falciparum there was relatively little variability in EC 50 values for chloroquine and dihydroartemisinin but large differences for pyrimethamine after a single 48 h exposure (Figure 2c ). For both species, variability between EC 50 values at different initial life cycle stages was markedly reduced when samples were read after two cycles (Figure 2b and d) .
The fluorescence method yielded good Z 0 factors of between 0.6 and 0.91 for P. knowlesi (Figure 2e and f) and between 0.75 and 0.89 for P. falciparum (Figure 2g and h) , supporting the use of the SYBR Green I method for assays initiated at 1% parasitaemia and 1% haematocrit on parasites of varying synchrony. For both species, timing of initiation of the experiment and use of double life cycle exposure were important determinants of quality ( Synchronized assays read by the LDH method ( Figure S2 ) showed a similar pattern to those read for the fluorescence assay after one cycle. Highly variable EC 50 estimates were obtained with chloroquine in P. knowlesi, and pyrimethamine in P. falciparum, depending on the initial life cycle stage. For P. knowlesi, EC 50 values could not be obtained for pyrimethamine in 27 h experiments initiated in early trophozoites ( Figure S2A ), even though estimates were readily obtained using the SYBR Green I method (Figure 2a ). This suggests that short exposures of pyrimethamine were able to inhibit DNA replication but not LDH activity in P. knowlesi. By the second life cycle exposure LDH activity was inhibited at higher drug concentrations and all assays yielded EC 50 values ( Figure S2B) . Similarly, one of the P. falciparum curves for pyrimethamine failed to yield an EC 50 estimate after 48 h exposure but was able to generate data after 96 h exposure. This is clearly a weakness of enzyme-based assays for measuring parasite growth and may lead to otherwise active, potent compounds being incorrectly Figure 1 . Influence of starting parasitaemia of P. knowlesi (A1-H.1) and P. falciparum (3D7) on assay quality for both the fluorescent and colorimetric methods. Parasites set to 1% haematocrit and varying parasitaemia (0.1%-2%) were cultured in the presence or absence of a supralethal concentration of chloroquine for 27 h (circles), 54 h (squares) or 81 h (diamonds) for P. knowlesi, and 48 h (cirlces) or 96 h (squares) for P. falciparum. Upon termination of the assay, the plates were read using either the SYBR Green I fluorescence assay (a, c, e and g) or the LDH assay (b, d, f and h). The signal window and Z 0 factor were calculated for each assay. The signal window was calculated by dividing the average reading for the drug-free control by the average reading for the high chloroquine concentration (background) control. The assay quality was assessed by determining the Z 0 factor using the formula described in Zhang et al.
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Antimalarial susceptibility of Plasmodium knowlesi in vitro JAC rejected if the timing or duration of exposure is non-optimal. As in the previous assays, two-cycle experiments greatly reduced any variation in EC 50 caused by altering the initial life cycle stage.
Whilst the LDH assays performed on P. falciparum were of good quality ( Figure S2G and H) , the assays on P. knowlesi performed poorly with a small signal window and low Z 0 factor after a single life cycle (,2; Figure S2E ). Signal and assay quality improved with double life cycle exposure (Z 0 range " 0.51-0.77; Figure S2F ). This suggests that, for P. knowlesi, the LDH assay is not ideal for shortexposure drug assays initiated at 1% parasitaemia and 1% haematocrit. The LDH assay is suitable for P. falciparum drug assays but caution is needed when examining the effect of antifolates such as pyrimethamine. Although EC 50 results for synchronous singlecycle experiments varied dramatically depending on the initial life cycle stage in P. knowlesi (Figure 2a) , the mean EC 50 obtained from these synchronized assay data closely approximated the EC 50 estimates from experiments on non-synchronous parasites ( Figure  S3 ). Thus, in addition to being logistically simpler, the nonsynchronous experiments can ameliorate the variation observed due to stage-specific effects in synchronous experiments. Considering this, and the variable performance of the LDH platform, all subsequent susceptibility testing in P. knowlesi deployed the non-synchronous fluorescent SYBR Green I method.
Activity of antimalarial agents
Using starting conditions of 1% parasitaemia and 1% haematocrit, we compared the drug susceptibility of P. knowlesi and P. falciparum (3D7) exposed for one complete life cycle. As P. knowlesi requires media heavily supplemented with Albumax/ serum, all EC 50 experiments were carried out in the P. knowlesi media, which readily supports growth of both parasite species. This removes the confounding effect of serum protein levels on EC 50 estimates for certain drugs (e.g. atovaquone; Table S1 ).
The susceptibility of P. knowlesi to the 4-aminoquinolines and amino-alcohols was similar to that of P. falciparum (Table 1 ). All EC 50 estimates for P. knowlesi fell below 100 nM and within 2.5-fold of the EC 50 reported for P. falciparum (Table 1) . Although the EC 50 differences were not large between species, several were statistically significant (P 0.0424). Ferroquine, currently in Phase II trials, was highly potent against P. knowlesi (12.2 nM; Table 1 ).
Presently, artemisinin-based combination therapy is recommended for the treatment of uncomplicated P. knowlesi malaria. 19 Artesunate, dihydroartemisinin and a synthetic endoperoxide, OZ439, were all highly potent against both parasite species, with P. knowlesi significantly more susceptible to dihydroartemisinin than P. falciparum (Table 1 ; P " 0.0098).
Interestingly, we found P. knowlesi parasites to be highly susceptible to dihydrofolate reductase (DHFR) inhibitors, being more than 9-fold more susceptible to pyrimethamine, cycloguanil and trimethoprim than the drug-susceptible P. falciparum line tested here. However, both species showed similar susceptibility (4 nM) to the new DHFR inhibitor P218, designed to overcome resistant forms of the P. falciparum enzyme. 20 Thus existing medicines such as sulfadoxine/pyrimethamine may prove to be very effective agents against P. knowlesi, both for treatment and prophylaxis. Future studies should explore the impact of both DHFR and dihydropteroate synthase inhibitors on P. knowlesi metabolism in depth, the latter requiring specialized growth media sufficiently Figure 2 . Effect of synchrony on drug susceptibility measured across the life cycle using the SYBR Green I method after one or two life cycles. EC 50 values for chloroquine (squares), dihydroartemisinin (circles) or pyrimethamine (diamonds) were determined from experiments initiated at the times shown on the y-axis using synchronized parasites at 1% parasitemia and 1% haematocrit that were incubated for either 27 h (a) or 54 h (b) for P. knowlesi, and 48 h (c) or 96 h (d) for P. falciparum. Signal window (squares) and assay quality (Z 0 factor, circles) (e-h) were determined as in Figure 1. van Schalkwyk et al.
depleted of folate and para-aminobenzoic acid, 21 ,22 and so not tested here.
Transfection reagents
We tested P. knowlesi susceptibility to three common selective agents used to favour growth of transfected P. falciparum parasites harbouring exogenous DNA. The DHFR inhibitor WR99210 was highly potent against P. knowlesi with an EC 50 value of 0.16+0.04 nM. Similar to other DHFR inhibitors tested, WR99210 was significantly more potent against P. knowlesi than against P. falciparum (0.43+0.03 nM; P " 0.0003). Blasticidin was 22-fold less potent against P. knowlesi when compared with P. falciparum (Table 1 ) over a single life cycle, which is consistent with a previous report, 7 in which P. knowlesi H strain was grown in rhesus erythrocytes. Reduced susceptibility of P. knowlesi to blasticidin prevents its use as a selectable marker at the concentrations generally used for transfection studies. Similarly, P. knowlesi was also 3-fold less susceptible than 3D7 to DSM1 (Table 1) ; dihydroorotate dehydrogenase (DHODH)-containing plasmid selection with DSM1 needs to be conducted at higher concentrations for this species.
P. knowlesi and P. falciparum were both highly susceptible to the mitochondrial cytochrome b inhibitor atovaquone (Table 1) , but both poorly susceptible to primaquine in vitro with EC 50 values at micromolar concentrations.
DHODH inhibitors
The DHODH enzyme is a newly validated antimalarial target. 18, [23] [24] [25] Several inhibitors of this enzyme have been identified and the two most advanced, DSM421 and DSM265, are currently in preclinical and Phase II trials. 23, 25 Considering the reduced potency of the transfection reagent DSM1 against P. knowlesi versus P. falciparum, we tested other DHODH inhibitors against P. knowlesi (Table 2 ). All compounds were 2.7-fold more potent against P. falciparum than against P. knowlesi whether tested over one or two life cycles. These agents are undergoing development for their potential use as antimalarial agents (http://www.mmv.org/research-development/interactiverd-portfolio). c These compounds are used in transfection studies with P. falciparum to select for parasites that harbour plasmids carrying drug resistance cassettes.
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In particular, DSM265 was 8-fold more potent against P. falciparum (Table 2 ). This supports previous observations suggesting that P. knowlesi was less susceptible to DHODH inhibitors than P. falciparum. 18 However, in that study the two species were tested under completely discordant assay conditions. Whether P. knowlesi is less susceptible than P. falciparum to the effects of DHODH inhibitors because of differences in enzyme activity, access to the enzyme or fundamental differences in the biology of these parasites remains to be established. Of note, DSM265 was shown to be about 5-fold more active against P. falciparum field isolates than Plasmodium vivax field isolates ex vivo, while DSM421 was equipotent against both species, 25 reinforcing the relevance of using P. knowlesi drug susceptibility testing to inform drug development for P. vivax. 
Delayed death effect
Antibacterial agents, such as azithromycin and clindamycin, have been shown to exert potent activity against P. falciparum in vitro but only after two complete asexual life cycles (96 h). 26 This phenomenon is referred to as the delayed death effect, and has also been reported for clindamycin against P. knowlesi in vitro. 8 In our experiments, a delayed death effect in P. knowlesi is confirmed for clindamycin, doxycycline and azithromycin (Table 3) . EC 50 values for P. knowlesi were measured over three life cycles (81 h), as additional time was required to resolve the full delayed drug effect in our experiments using unsynchronized cultures. For P. falciparum parasites the assay used synchronized parasites, and therefore, two cycles (96 h) were sufficient to detect the delayed death effect. Azithromycin was equally potent between species over a single life cycle (P " 0.4397) and not significantly different in its delayed death effect (P " 0.2514). Similarly, clindamycin had no measurable effect over a single life cycle in either species but was very potent against P. knowlesi (15.9 nM) and P. falciparum (7.0 nM) over 81 and 96 h, respectively. For doxycycline the delayed death potency for P. knowlesi was much reduced (2061 nM) relative to P. falciparum (623 nM). We noted that the delayed death curves did not level out to 0% viability but were asymptotic at about 25% viability, presumably due to the greater All inhibitors were tested in duplicate on three separate occasions from a starting parasitaemia and haematocrit of 1%. The EC 50 values are reported as the mean + SEM. The fold difference is calculated by dividing the P. knowlesi EC 50 value by the P. falciparum EC 50 value. For each DSM compound, the mean P. falciparum EC 50 value was significantly lower than the mean P. knowlesi EC 50 value when compared over either a single parasite life cycle or over two life cycles (P 0.0018). Clindamycin .10000
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All antibacterial agents were screened in duplicate on at least three separate occasions from a starting parasitaemia and haematocrit of 1%. The EC 50 values are reported as the mean + SEM. The fold difference for each compound is calculated by dividing the EC 50 value after three life cycles (for P. knowlesi) or two life cycles (for P. falciparum) by the EC 50 value measured after a single life cycle exposure. van Schalkwyk et al.
amount of residual DNA from parasites surviving the first cycle of growth compared with the chloroquine control wells in which parasites die in the first cycle. This was corrected for clindamycin and doxycycline, but not azithromycin, by using a background control generated for the second cycle only ( Figure S4 ).
Drug susceptibility of P. knowlesi grown in human versus macaque blood
We assessed the effect of culturing P. knowlesi parasites in human versus macaque erythrocytes on susceptibility to a subset of antimalarials (Table 4) . No significant host-specific differences in potency were observed, although it was evident that the EC 50 values were generally higher in parasites grown in macaque erythrocytes (Table 4 ). This could be related to higher growth rates of P. knowlesi parasites in macaque cells, estimated at 5-to 7-fold compared with 3-to 4-fold in human erythrocytes. 6 The P. knowlesi A1-H.1 is descended from a 1964 macaque isolate and is assumed to be drug susceptible. 27, 28 Using identical growth media and viability readouts, we expected to find EC 50 estimates very similar to those for P. falciparum 3D7 for most, if not all, antimalarials tested. The unexpected differences in susceptibility to DHFR inhibitors (pyrimethamine, cycloguanil and trimethoprim) and DHODH inhibitors suggest that important species-specific differences in drug responses exist. A recent study reported the in vitro activity of the 400 compound Malaria Box against P. falciparum 3D7 and showed that 90% were also active against P. knowlesi yH-1 strain. 29 Closer examination of those data show that EC 50 estimates for 52 compounds were at least 3-fold higher or lower for P. knowlesi than for P. falciparum.
Conclusions
We have provided detailed validation of a fluorescent assay system for drug susceptibility testing in P. knowlesi. This provides an important new tool for in vitro drug studies in non-P. falciparum malaria. Significant species-specific differences in susceptibility to certain compound classes was observed, highlighting the added value of in vitro screens against additional human malaria pathogens. The generalizability of our findings should now be tested in recent P. knowlesi field isolates from geographically distinct regions of South-East Asia.
